Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type 1 receptor blockers

Drug, Healthcare and Patient Safety

Volumn 2, Issue 1, 2010, Pages 21-25

  Ekman, Elisabet ^a   Hägg, Staffan ^b   Sundström, Anders ^c   Werkström, Viktoria ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adverse drug reaction; Angiotensin II type 1 receptor blockers; Antihypertensive drugs; Erectile dysfunction; Spontaneous reporting

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CITALOPRAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FELODIPINE; LOSARTAN; METOPROLOL; RAMIPRIL; TADALAFIL; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG RECHALLENGE; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; HUMAN; MALE; RISK FACTOR; SELF REPORT;

EID: 77953387862     PISSN: None     EISSN: 11791365     Source Type: Journal    
DOI: 10.2147/dhps.s8432     Document Type: Article

References (23)

1. Hatzimouratidis K, Hatzichristou D. Sexual dysfunctions: classifications and definitions. J Sex Med. 2007;4(1):241-250.
2. Dusing R. Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs. 2005;65(6):773-786.
3. Kloner R. Erectile dysfunction and hypertension. Int J Impot Res. 2007;19(3):296-302.
4. Stadler T, Bader M, Uckert S, Staehler M, Becker A, Stief CG. Adverse effects of drug therapies on male and female sexual function. World J Urol. 2006 Dec; 24(6):623-629.
5. Kloner RA, Mullin SH, Shook T, et al. Erectile dysfunction in the cardiac patient: how common and should we treat? J Urol. 2003;170 (2 Pt 2):Suppl 46-50.
6. Papatsoris AG, Korantzopoulos PG. Hypertension, antihypertensive therapy, and erectile dysfunction. Angiology. 2006;57(1):47-52.
7. Reffelmann T, Kloner RA. Sexual function in hypertensive patients receiving treatment. Vasc Health Risk Manag. 2006;2(4):447-455.
8. Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens. 2001;14(1):27-31.
9. Llisterri JL, Lozano Vidal JV, Aznar Vicente J, et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci. 2001;321(5):336-341.
10. Della Chiesa A, Pfiffner D, Meier B, Hess OM. Sexual activity in hypertensive men. J Hum Hypertens. 2003;17(8):515-521.
11. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315-321.
12. Bate A, Lindquist M, Orre R, Edwards IR, Meyboom RH. Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs. Eur J Clin Pharmacol. 2002;58(7):483-490.
13. van Puijenbroek EP, Bate A, Leufkens HG, Lindquist M, Orre R, Egberts AC. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3-10.
14. Lindquist M, Edwards IR, Bate A, Fucik H, Nunes AM, Stahl M. From association to alert - a revised approach to international signal analysis. Pharmacoepidemiol Drug Saf. 1999;8 Suppl 1:S15-S25.
15. Rosen RC, Marin H. Prevalence of antidepressant-associated erectile dysfunction. J Clin Psychiatry. 2003;64 Suppl 10:5-10.
16. Grover SA, Lowensteyn I, Kaouache M, et al. The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch Intern Med. 2006;166(2): 213-219.
17. Wallenstein EJ, Fife D. Temporal patterns of NSAID spontaneous adverse event reports: the Weber effect revisited. Drug Saf. 2001;24(3):233-237.
18. McAdams MA, Governale LA, Swartz L, Hammad TA, Dal Pan GJ. Identifying patterns of adverse event reporting for four members of the angiotensin II receptor blockers class of drugs: revisiting the Weber effect. Pharmacoepidemiol Drug Saf. 2008;17(9):882-889.
19. Becker AJ, Uckert S, Stief CG, et al. Possible role of bradykinin and angiotensin II in the regulation of penile erection and detumescence. Urology. 2001;57(1):193-198.
20. Chen Y, Li SX, Yao LS, Wang R, Dai YT. Valsartan treatment reverses erectile dysfunction in diabetic rats. Int J Impot Res. 2007;19(4): 366-370.
21. Alvarez-Requejo A, Carvajal A, Begaud B, Moride Y, Vega T, Arias LH. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol. 1998;54(6):483-488.
22. Ekman E, Backstrom M. Attitudes among hospital physicians to the reporting of adverse drug reactions in Sweden. Eur J Clin Pharmacol. 2009;65(1):43-46.
23. Tomlinson J. ABC of sexual health: taking a sexual history. BMJ. 1998;317(7172):1573-1576.